InsidersTradesSigma
Track the Jiangsu Hengrui Pharmaceuticals Co., Ltd. share price and the full management transaction log of the company, a listed equity based in Hong Kong. Shares are quoted on the HK market, under the authority of HKEX. Operating in the Health Care sector, Jiangsu Hengrui Pharmaceuticals Co., Ltd. has logged 7 public disclosures. Market capitalisation: €376bn. The latest transaction was disclosed on 29 April 2026 (Other). Among the most active insiders: Lou Liguang. The full history is free.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
5 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Jiangsu Hengrui Pharmaceuticals Co., Ltd. Strong Buy (bullish), based on 9 analysts. Average price target: HK$95.22.
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 7,724 of 29,064 companies
63.2
score / 100
Value37
Quality89
FCF yld2.7%
Earn yld2.5%
EV/EBITDA32.2x
ROE15%
Gross mgn86%
Net mgn24%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 29 April 2026
Declarations7 total
1,000 sharesShareXHKGHKEX:DA20260428E00444
10,180 sharesShareXHKGHKEX:DA20260428E00443
99,000 sharesShareXHKGHKEX:DA20260402E00226
81,000 sharesShareXHKGHKEX:DA20260402E00275
49,000 sharesShareXHKGHKEX:DA20260402E00289
81,000 sharesShareXHKGHKEX:DA20260402E00267
7 of 7 declarations
关于 Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江苏恒瑞医药股份有限公司是一家中国制药公司，从事药品的研发和制造。该公司在香港证券交易所上市，专注于医疗保健领域的创新。